L Rhoda Molife
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study(2009)338 cited
- → Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor(2012)334 cited
- → Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors(2007)266 cited
- → Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers(2012)146 cited
- → Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?(2011)137 cited
- → An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib(2016)129 cited
- → Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer(2011)126 cited
- → Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management(2016)62 cited
- → FGF Receptor Inhibitors: Role in Cancer Therapy(2012)60 cited
- → Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours(2015)51 cited